3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
8
Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Leukemia, Myeloid, Acute
4
Hematologic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Pulmonary Disease, Chronic Obstructive
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Leukemia
2
Colonic Neoplasms
2
COVID-19
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stroke
1
Stomatitis
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
Methotrexate
48
Cyclophosphamide
47
Vincristine
39
Cytarabine
36
Dexamethasone
33
Mercaptopurine
32
pegaspargase
30
Doxorubicin
29
Daunorubicin
26
Etoposide
24
Asparaginase
23
Prednisone
22
Radiotherapy
18
Thioguanine
15
Leucovorin
14
Calcium Dobesilate
14
merphos
12
Prednisolone
12
blinatumomab
11
Hydrocortisone
10
Whole-Body Irradiation
9
dexamethasone acetate
8
azathiopurine
8
Methylprednisolone
8
Ifosfamide
8
Filgrastim
8
Cyclosporine
8
fludarabine
7
dexamethasone 21-phosphate
7
auricularum
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts